Welcome!

News Feed Item

Multiple Sclerosis Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Multiple Sclerosis Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02256139/Multiple-Sclerosis-Global-Clinical-Trials-Review-H2-2014.html

Multiple Sclerosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Multiple Sclerosis Global Clinical Trials Review, H2, 2014" provides data on the Multiple Sclerosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Multiple Sclerosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Multiple Sclerosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Multiple Sclerosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Multiple Sclerosis 25
Subjects Recruited Over a Period of Time 35
Clinical Trials by Sponsor Type 36

Prominent Sponsors 37
Top Companies Participating in Multiple Sclerosis Therapeutics Clinical Trials 38
Prominent Drugs 40
Latest Clinical Trials News on Multiple Sclerosis 41
Jun 16, 2014: Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis 41
May 27, 2014: Bionure MS Drug Candidate Shows Positive Results for Myelin Repair in Cell Culture Assay 41
Clinical Trial Profiles 43
Clinical Trial Overview of Top Companies 43
Biogen Idec Inc. 43
Clinical Trial Overview of Biogen Idec Inc. 43
E. Merck KG 53
Clinical Trial Overview of E. Merck KG 53
Novartis AG 59
Clinical Trial Overview of Novartis AG 59
Teva Pharmaceutical Industries Limited 64
Clinical Trial Overview of Teva Pharmaceutical Industries Limited 64
Bayer AG 68
Clinical Trial Overview of Bayer AG 68

Sanofi 72
Clinical Trial Overview of Sanofi 72
GlaxoSmithKline plc 75
Clinical Trial Overview of GlaxoSmithKline plc 75
Acorda Therapeutics, Inc. 77
Clinical Trial Overview of Acorda Therapeutics, Inc. 77
Elan Corporation, plc 79
Clinical Trial Overview of Elan Corporation, plc 79
Pfizer Inc. 80
Clinical Trial Overview of Pfizer Inc. 80
Clinical Trial Overview of Top Institutes / Government 81
National Institute of Neurological Disorders and Stroke 81
Clinical Trial Overview of National Institute of Neurological Disorders and Stroke 81
Charite - Universitatsmedizin Berlin 83
Clinical Trial Overview of Charite - Universitatsmedizin Berlin 83
Tehran University of Medical Sciences 84
Clinical Trial Overview of Tehran University of Medical Sciences 84
U.S. Department of Veterans Affairs 85
Clinical Trial Overview of U.S. Department of Veterans Affairs 85
Oregon Health & Science University 86
Clinical Trial Overview of Oregon Health & Science University 86
The National Institute of Allergy and Infectious Diseases 87

Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases 87
University of Washington 88
Clinical Trial Overview of University of Washington 88
St. Andrea Hospital Sapienza Rome University 89
Clinical Trial Overview of St. Andrea Hospital Sapienza Rome University 89
Imperial College London 90
Clinical Trial Overview of Imperial College London 90
Department of Health, UK 91
Clinical Trial Overview of Department of Health, UK 91
Five Key Clinical Profiles 92
Appendix 196
Abbreviations 196
Definitions 196
Research Methodology 197
Secondary Research 197
About GlobalData 198
Contact Us 198
Disclaimer 198
Source 198

List of Tables

Multiple Sclerosis Therapeutics, Global, Clinical Trials by Region, 2014* 7
Multiple Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Multiple Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Multiple Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Multiple Sclerosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Multiple Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Multiple Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Phase, 2014* 21

Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Multiple Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Multiple Sclerosis Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Multiple Sclerosis Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Multiple Sclerosis Therapeutics, Global, Terminated Clinical Trials, 2014* 28
Multiple Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 35
Multiple Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 36
Multiple Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 37
Multiple Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 39
Multiple Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 40
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Biogen Idec Inc., 2014* 43
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by E. Merck KG, 2014* 53
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 59

Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Teva Pharmaceutical Industries Limited, 2014* 64
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 68
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 72
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 75
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Acorda Therapeutics, Inc., 2014* 77
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Elan Corporation, plc, 2014* 79
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 80
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014* 81
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Charite - Universitatsmedizin Berlin, 2014* 83
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 84
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2014* 85

Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Oregon Health & Science University, 2014* 86
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014* 87
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Washington, 2014* 88
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by St. Andrea Hospital Sapienza Rome University, 2014* 89
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Imperial College London, 2014* 90
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Department of Health, UK, 2014* 91

List of Figures

Multiple Sclerosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Multiple Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Multiple Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Multiple Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Multiple Sclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Multiple Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Multiple Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18

Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Multiple Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Multiple Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 35
Multiple Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 36
Multiple Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 37
Multiple Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 38
Multiple Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 40
GlobalData Methodology 197

To order this report: Multiple Sclerosis Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02256139/Multiple-Sclerosis-Global-Clinical-Trials-Review-H2-2014.html

_________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
Automation is enabling enterprises to design, deploy, and manage more complex, hybrid cloud environments. Yet the people who manage these environments must be trained in and understanding these environments better than ever before. A new era of analytics and cognitive computing is adding intelligence, but also more complexity, to these cloud environments. How smart is your cloud? How smart should it be? In this power panel at 20th Cloud Expo, moderated by Conference Chair Roger Strukhoff, pane...
@DevOpsSummit at Cloud Expo taking place Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center, Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is ...
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists examined how DevOps helps to meet the de...
No hype cycles or predictions of zillions of things here. IoT is big. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, Associate Partner at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He discussed the evaluation of communication standards and IoT messaging protocols, data analytics considerations, edge-to-cloud tec...
When growing capacity and power in the data center, the architectural trade-offs between server scale-up vs. scale-out continue to be debated. Both approaches are valid: scale-out adds multiple, smaller servers running in a distributed computing model, while scale-up adds fewer, more powerful servers that are capable of running larger workloads. It’s worth noting that there are additional, unique advantages that scale-up architectures offer. One big advantage is large memory and compute capacity...
In 2014, Amazon announced a new form of compute called Lambda. We didn't know it at the time, but this represented a fundamental shift in what we expect from cloud computing. Now, all of the major cloud computing vendors want to take part in this disruptive technology. In his session at 20th Cloud Expo, Doug Vanderweide, an instructor at Linux Academy, discussed why major players like AWS, Microsoft Azure, IBM Bluemix, and Google Cloud Platform are all trying to sidestep VMs and containers wit...
What's the role of an IT self-service portal when you get to continuous delivery and Infrastructure as Code? This general session showed how to create the continuous delivery culture and eight accelerators for leading the change. Don Demcsak is a DevOps and Cloud Native Modernization Principal for Dell EMC based out of New Jersey. He is a former, long time, Microsoft Most Valuable Professional, specializing in building and architecting Application Delivery Pipelines for hybrid legacy, and cloud ...
Amazon started as an online bookseller 20 years ago. Since then, it has evolved into a technology juggernaut that has disrupted multiple markets and industries and touches many aspects of our lives. It is a relentless technology and business model innovator driving disruption throughout numerous ecosystems. Amazon’s AWS revenues alone are approaching $16B a year making it one of the largest IT companies in the world. With dominant offerings in Cloud, IoT, eCommerce, Big Data, AI, Digital Assista...
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business - from apparel to energy - is being rewritten by software. From planning to development to management to security, CA creates software that fuels transformation for companies in the applic...
Artificial intelligence, machine learning, neural networks. We’re in the midst of a wave of excitement around AI such as hasn’t been seen for a few decades. But those previous periods of inflated expectations led to troughs of disappointment. Will this time be different? Most likely. Applications of AI such as predictive analytics are already decreasing costs and improving reliability of industrial machinery. Furthermore, the funding and research going into AI now comes from a wide range of com...
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists looked at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deliver...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devic...
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.